Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji

Felisita Tupou Ratu, Rita Reyburn, Evelyn Tuivaga, Asena Tuiketei, Kylie Jenkins, Kim Mulholland, Adam Jenney, Fiona Russell

    Research output: Contribution to journalArticleResearchpeer-review

    6 Downloads (Pure)

    Abstract

    In 2012, Fiji introduced rotavirus vaccine (Rotarix, GSK) into the national immunisation schedule. We describe the intussusception epidemiology prior to rotavirus vaccine, temporal association of intussusception cases to administration of rotavirus vaccine, and estimate the additional number of intussusception cases that may be associated with rotavirus vaccine. A retrospective review of intussusception cases for children aged <24 months old was undertaken between January 2007 and October 2012 pre-vaccine. All admissions and deaths with a discharge diagnosis of intussusception, bowel obstruction, paralytic ileus, or intussusception ICD10-AM codes were extracted from national databases and hospital records. Nationwide active intussusception surveillance was established for three years post-vaccine (2013–2015). There were 24 definite intussusception cases in the pre-rotavirus vaccine period, 96% were confirmed by surgery. The median age was 6.5 months. The incidence rate was 22.2 (95% CI: 13.9–33.7) per 100,000 infants. There were no deaths. Active surveillance identified 25 definite intussusception cases, 96% of which were among children who were age-eligible for rotavirus vaccine. None were potentially vaccine related. We estimated one to five additional cases of intussusception every five years. The incidence of intussusception pre-rotavirus vaccine in Fiji is low. Intussusception associated with rotavirus vaccine is likely a rare event in Fiji.

    Original languageEnglish
    Article number11194
    Pages (from-to)1-6
    Number of pages6
    JournalScientific Reports
    Volume8
    Issue number1
    Early online date25 Jul 2018
    DOIs
    Publication statusPublished - 1 Dec 2018

    Fingerprint

    Fiji
    Rotavirus Vaccines
    Intussusception
    Epidemiology
    Vaccines
    Immunization Schedule
    Intestinal Pseudo-Obstruction
    Hospital Records
    Incidence

    Cite this

    Ratu, F. T., Reyburn, R., Tuivaga, E., Tuiketei, A., Jenkins, K., Mulholland, K., ... Russell, F. (2018). Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji. Scientific Reports, 8(1), 1-6. [11194]. https://doi.org/10.1038/s41598-018-29515-2
    Ratu, Felisita Tupou ; Reyburn, Rita ; Tuivaga, Evelyn ; Tuiketei, Asena ; Jenkins, Kylie ; Mulholland, Kim ; Jenney, Adam ; Russell, Fiona. / Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji. In: Scientific Reports. 2018 ; Vol. 8, No. 1. pp. 1-6.
    @article{49b15a733f704a50ae8314e9a7a06f9e,
    title = "Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji",
    abstract = "In 2012, Fiji introduced rotavirus vaccine (Rotarix, GSK) into the national immunisation schedule. We describe the intussusception epidemiology prior to rotavirus vaccine, temporal association of intussusception cases to administration of rotavirus vaccine, and estimate the additional number of intussusception cases that may be associated with rotavirus vaccine. A retrospective review of intussusception cases for children aged <24 months old was undertaken between January 2007 and October 2012 pre-vaccine. All admissions and deaths with a discharge diagnosis of intussusception, bowel obstruction, paralytic ileus, or intussusception ICD10-AM codes were extracted from national databases and hospital records. Nationwide active intussusception surveillance was established for three years post-vaccine (2013–2015). There were 24 definite intussusception cases in the pre-rotavirus vaccine period, 96{\%} were confirmed by surgery. The median age was 6.5 months. The incidence rate was 22.2 (95{\%} CI: 13.9–33.7) per 100,000 infants. There were no deaths. Active surveillance identified 25 definite intussusception cases, 96{\%} of which were among children who were age-eligible for rotavirus vaccine. None were potentially vaccine related. We estimated one to five additional cases of intussusception every five years. The incidence of intussusception pre-rotavirus vaccine in Fiji is low. Intussusception associated with rotavirus vaccine is likely a rare event in Fiji.",
    author = "Ratu, {Felisita Tupou} and Rita Reyburn and Evelyn Tuivaga and Asena Tuiketei and Kylie Jenkins and Kim Mulholland and Adam Jenney and Fiona Russell",
    year = "2018",
    month = "12",
    day = "1",
    doi = "10.1038/s41598-018-29515-2",
    language = "English",
    volume = "8",
    pages = "1--6",
    journal = "Scientific Reports",
    issn = "2045-2322",
    publisher = "Nature Publishing Group",
    number = "1",

    }

    Ratu, FT, Reyburn, R, Tuivaga, E, Tuiketei, A, Jenkins, K, Mulholland, K, Jenney, A & Russell, F 2018, 'Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji', Scientific Reports, vol. 8, no. 1, 11194, pp. 1-6. https://doi.org/10.1038/s41598-018-29515-2

    Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji. / Ratu, Felisita Tupou; Reyburn, Rita; Tuivaga, Evelyn; Tuiketei, Asena; Jenkins, Kylie; Mulholland, Kim; Jenney, Adam; Russell, Fiona.

    In: Scientific Reports, Vol. 8, No. 1, 11194, 01.12.2018, p. 1-6.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji

    AU - Ratu, Felisita Tupou

    AU - Reyburn, Rita

    AU - Tuivaga, Evelyn

    AU - Tuiketei, Asena

    AU - Jenkins, Kylie

    AU - Mulholland, Kim

    AU - Jenney, Adam

    AU - Russell, Fiona

    PY - 2018/12/1

    Y1 - 2018/12/1

    N2 - In 2012, Fiji introduced rotavirus vaccine (Rotarix, GSK) into the national immunisation schedule. We describe the intussusception epidemiology prior to rotavirus vaccine, temporal association of intussusception cases to administration of rotavirus vaccine, and estimate the additional number of intussusception cases that may be associated with rotavirus vaccine. A retrospective review of intussusception cases for children aged <24 months old was undertaken between January 2007 and October 2012 pre-vaccine. All admissions and deaths with a discharge diagnosis of intussusception, bowel obstruction, paralytic ileus, or intussusception ICD10-AM codes were extracted from national databases and hospital records. Nationwide active intussusception surveillance was established for three years post-vaccine (2013–2015). There were 24 definite intussusception cases in the pre-rotavirus vaccine period, 96% were confirmed by surgery. The median age was 6.5 months. The incidence rate was 22.2 (95% CI: 13.9–33.7) per 100,000 infants. There were no deaths. Active surveillance identified 25 definite intussusception cases, 96% of which were among children who were age-eligible for rotavirus vaccine. None were potentially vaccine related. We estimated one to five additional cases of intussusception every five years. The incidence of intussusception pre-rotavirus vaccine in Fiji is low. Intussusception associated with rotavirus vaccine is likely a rare event in Fiji.

    AB - In 2012, Fiji introduced rotavirus vaccine (Rotarix, GSK) into the national immunisation schedule. We describe the intussusception epidemiology prior to rotavirus vaccine, temporal association of intussusception cases to administration of rotavirus vaccine, and estimate the additional number of intussusception cases that may be associated with rotavirus vaccine. A retrospective review of intussusception cases for children aged <24 months old was undertaken between January 2007 and October 2012 pre-vaccine. All admissions and deaths with a discharge diagnosis of intussusception, bowel obstruction, paralytic ileus, or intussusception ICD10-AM codes were extracted from national databases and hospital records. Nationwide active intussusception surveillance was established for three years post-vaccine (2013–2015). There were 24 definite intussusception cases in the pre-rotavirus vaccine period, 96% were confirmed by surgery. The median age was 6.5 months. The incidence rate was 22.2 (95% CI: 13.9–33.7) per 100,000 infants. There were no deaths. Active surveillance identified 25 definite intussusception cases, 96% of which were among children who were age-eligible for rotavirus vaccine. None were potentially vaccine related. We estimated one to five additional cases of intussusception every five years. The incidence of intussusception pre-rotavirus vaccine in Fiji is low. Intussusception associated with rotavirus vaccine is likely a rare event in Fiji.

    UR - http://www.scopus.com/inward/record.url?scp=85050677219&partnerID=8YFLogxK

    U2 - 10.1038/s41598-018-29515-2

    DO - 10.1038/s41598-018-29515-2

    M3 - Article

    VL - 8

    SP - 1

    EP - 6

    JO - Scientific Reports

    JF - Scientific Reports

    SN - 2045-2322

    IS - 1

    M1 - 11194

    ER -

    Ratu FT, Reyburn R, Tuivaga E, Tuiketei A, Jenkins K, Mulholland K et al. Epidemiology of intussusception before and after rotavirus vaccine introduction in Fiji. Scientific Reports. 2018 Dec 1;8(1):1-6. 11194. https://doi.org/10.1038/s41598-018-29515-2